SUWANEE, GA, May 09, 2018 (GLOBE NEWSWIRE) — SANUWAVE Health, Inc. (OTCQB: SNWV) is pleased to announce that it has appointed AMBIENSYS SRL as the distributor for the dermaPACE® System in Romania. The expected revenue from this agreement will be north of $400,000 over the next three years.
Globally, AMBIENSYS SRL is known as a service provider in the areas of consulting, training in European funding, project management and implementation. AMBIENSYS SRL strives to provide clients with comprehensive information and services on funding opportunities, funding preparation, training and technical assistance during project implementation. AMBIENSYS SRL’s intent is to contribute to commercialization strength locally and regionally to sustainable innovations like the dermaPACE® System. After successful training, the cognitive and clinical knowledge will be transferred by Certified Trainers at AMBIENSYS SRL to hospitals throughout Romania to ensure the safe and effective use of dermaPACE® consistent with approved labeling, EU requirements and a focus on best practices of patient care and comfort during treatments.
Kevin A. Richardson II, Chairman of the Board of SANUWAVE, stated, “The decision to engage AMBIENSYS SRL was made to introduce the dermaPACE® system throughout the wound care market in Romania, which is the largest country in Southeastern Europe. It is paramount that we partner with global distributors that have complementary contacts and a positive impact within the local Romanian market. It is well known that diabetes and related concerns need to be addressed within Romania and having access to outstanding technology such as SANUWAVE’s within the country is a remediable step towards a healthier tomorrow.”
Shipment of the first devices and training will occur in the second quarter of 2018 to AMBIENSYS SRL.
For more information on SANUWAVE’s technology, please read our blog, “Shock This”, on our website at www.sanuwave.com.
About AMBIENSYS SRL
AMBIENSYS SRL is registered as a consultancy and business development company with the Romanian Health Ministry and Romanian Agency for Medication and Medical Devices. The company is authorized for the import and distribution of medical devices on the Romanian market. AMBIENSYS SRL has the approval for the importation of dermaPACE® Systems from SANUWAVE. AMBIENSYS SRL is located in Ramnicu Valcea, Strada General Magheru, Nr. 25, SOCOM Building, Suite 67, Judetul Valcea.
Ing. Daniel Ioan Badescu
Ing. Dan Crisu Turcitu
Phone: (40) 0350 419 770
About SANUWAVE Health, Inc.
SANUWAVE Health, Inc. (OTCQB:SNWV) (www.sanuwave.com) is a shock wave technology company initially focused on the development and commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue and vascular structures. SANUWAVE’s portfolio of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses, producing new vascularization and microcirculatory improvement, which helps restore the body’s normal healing processes and regeneration. SANUWAVE applies its patented PACE technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product candidate for the global wound care market, dermaPACE®, is CE Marked throughout Europe and has device license approval for the treatment of the skin and subcutaneous soft tissue in Canada, Australia and New Zealand. In the U.S., dermaPACE® is currently under the FDA’s de novo petition review process for the treatment of diabetic foot ulcers. SANUWAVE researches, designs, manufactures, markets and services its products worldwide, and believes it has demonstrated that its technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S. Class III PMA approved OssaTron® device, as well as stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment through the utilization of its OssaTron, Evotron® and orthoPACE® devices in Europe, Asia and Asia/Pacific. In addition, there are license/partnership opportunities for SANUWAVE’s shock wave technology for non-medical uses, including energy, water, food and industrial markets.
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the regulatory approval and marketing of the Company’s product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Company’s ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.
For additional information about the Company, visit www.sanuwave.com.
Millennium Park Capital LLC Christopher Wynne 312-724-7845 firstname.lastname@example.org SANUWAVE Health, Inc. Kevin Richardson II Chairman of the Board 978-922-2447 email@example.com